Journal article

Switching on the green light for chimeric antigen receptor T-cell therapy

Sherly Mardiana, Junyun Lai, Imran Geoffrey House, Paul Andrew Beavis, Phillip Kevin Darcy



Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T-cell therapy in a subset of B-cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene-modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid c..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC)

Awarded by Cancer Council of Victoria

Awarded by National Breast Cancer Foundation Fellowship

Awarded by NHMRC Senior Research Fellowship

Funding Acknowledgements

This work was funded by a project and programme grant from the National Health and Medical Research Council (NHMRC; Grant number APP1062580 and APP1132373) and a project grant from the Cancer Council of Victoria (APP1143517). PA Beavis was supported by a National Breast Cancer Foundation Fellowship (ECF-17-005). PK Darcy was supported by a NHMRC Senior Research Fellowship (APP1136680).